

PPD expands clinical capabilities in China

15 January 2020 | News

Helping international pharmaceutical companies and Chinese biotechnology companies improve drug development



PPD, Inc. ([PPD](#)) has expanded its China operations and leadership team to provide more international and Chinese biopharmaceutical companies with more Comprehensive clinical development, laboratory, supervision, research unit implementation, patient recruitment and post-approval services.

PPD's expansion includes expanding its clinical development offices in Beijing and Shanghai, and opening new offices in Guangzhou and Shenyang. In 2020, [PPD® Laboratories](#) plans to set up a multifunctional laboratory in China to provide bioanalytical, biomarker and vaccine scientific services. In addition, the company's Accelerated Enrollment Solutions (AES) business, which provides unique research unit implementation and patient recruitment solutions, also incorporates China into its global business landscape. With its partnership with more than 300 hospitals in China, it provides Performance recruitment solutions.

PPD's expanding China business will be led by a new domestic leadership team, who have extensive experience in the pharmaceutical and biotechnology industries as well as China and the Asia Pacific region.

Dr. David Johnston, Executive Vice President of Global Clinical Development at PPD, said: "Recent changes in regulatory requirements have streamlined the drug development approval process in China, which has made China an important location for many global research and clinical trials. Our expanded China business It will enhance our capabilities to help multinational pharmaceutical companies better access China's growing drug development and post-marketing ecosystem, and to help Chinese biotech companies conduct trials in global markets. "

To oversee the expansion of China's business, PPD appointed Dr. Ding Ming, who has more than 20 years of industry experience, as vice president and general manager of the company's China business. Dr. Ming will lead PPD's various services in China, including global clinical development, PPD Laboratories, AES, PPD's near-approval and post-approval business Evidera, and China's business and functional support team.

Di Cindy Wu has been appointed as Executive Director of PPD Laboratories, which directly oversees the company's laboratory operations in China and Singapore, helps the company's laboratory operations maintain global consistency and continuity, and ensures the provision of high-quality test data. Wu has 18 years of experience in contract research organizations.

Christopher Fikry, Executive Vice President and Doctor of Medicine, PPD Laboratories said, "This year we plan to open a new laboratory in China that will greatly enhance our capabilities in the Asia-Pacific region. In the Asia-Pacific region, we have set up central laboratory in Shanghai and Singapore. This laboratory will have both bioanalytical, biomarker and vaccine laboratory capabilities, so the new laboratory will help us better meet the needs of our global customers and further build PPD into China's leading drug development laboratory. "

PPD refurbishes and greatly expands the size of its clinical development business in Beijing and Shanghai, and opened new offices in Guangzhou and Shenyang last year to support the growing number of clinical trials and help develop optimized supervision and access strategy. In August 2019, PPD launched a pharmacovigilance center in Shenyang to provide centralized services, such as full life-cycle safety monitoring capabilities, and rich expertise accumulated in China's regulatory environment to support China's growing demand for clinical research.

PPD's Regulatory Affairs team has extensive experience in China's ongoing regulatory reforms, and has a proven track record of helping clients successfully conduct business in the Chinese market. For more than 20 years, the company has been committed to providing full-service support for the development of Chinese trials, laying a solid foundation, which has enabled PPD to effectively and powerfully provide the necessary evidence on the value, safety and efficacy of drugs, thereby helping to obtain approval and enter the market of China. Last year, PPD facilitated more than 25 regulatory approvals in the Chinese market.